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ABSTRACT
Background. The rapid increase in antibiotic resistance by various bacterial pathogens
underlies the significance of developing new therapies and exploring different drug
targets. A fraction of bacterial pathogens abbreviated as ESKAPE by the European
Center for Disease Prevention and Control have been considered a major threat due
to the rise in nosocomial infections. Here, we compared putative drug binding pockets
of twelve essential and mostly conserved metabolic enzymes in numerous bacterial
pathogens including those of the ESKAPE group and Mycobacterium tuberculosis. The
comparative analysis will provide guidelines for the likelihood of transferability of the
inhibitors from one species to another.
Methods. Nine bacterial species including six ESKAPE pathogens, Mycobacterium tu-
berculosis along withMycobacterium smegmatis and Eschershia coli, two non-pathogenic
bacteria, have been selected for drug binding pocket analysis of twelve essential enzymes.
The amino acid sequences were obtained fromUniprot, aligned using ICM v3.8-4a and
matched against the Pocketome encyclopedia. We used known co-crystal structures
of selected target enzyme orthologs to evaluate the location of their active sites and
binding pockets and to calculate a matrix of pairwise sequence identities across each
target enzyme across the different species. This was used to generate sequence maps.
Results. High sequence identity of enzyme binding pockets, derived from experi-
mentally determined co-crystallized structures, was observed among various species.
Comparison at both full sequence level and for drug binding pockets of key metabolic
enzymes showed that binding pockets are highly conserved (sequence similarity up
to 100%) among various ESKAPE pathogens as well as Mycobacterium tuberculosis.
Enzymes orthologs having conserved binding sites may have potential to interact
with inhibitors in similar way and might be helpful for design of similar class of
inhibitors for a particular species. The derived pocket alignments and distance-based
maps provide guidelines for drug discovery and repurposing. In addition they also
provide recommendations for the relevant model bacteria that may be used for initial
drug testing.
Discussion. Comparing ligand binding sites through sequence identity calculation
could be an effective approach to identify conserved orthologs as drug binding pockets
have shown higher level of conservation among various species. By using this approach
we could avoid the problems associated with full sequence comparison. We identified
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essential metabolic enzymes among ESKAPE pathogens that share high sequence
identity in their putative drug binding pockets (up to 100%), of which known inhibitors
can potentially antagonize these identical pockets in the various species in a similar
manner.
Subjects Bioinformatics, Computational Biology, Microbiology, Pharmacology
Keywords ESKAPE Pathogens, Sequence alignment, Identity maps
INTRODUCTION
The European Centre for Disease Prevention and Control (ECDC) as well as The Infectious
Diseases Society of America (IDSA) have recently termed a set of difficult-to-treat
bacterial pathogens, Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae,
Acinetobacter baumannii, Pseudomonas aeruginosa and Enterobacter s pp, as ‘‘ESKAPE’’
pathogens given their propensity to develop resistance and ‘escape’ from current antibiotics,
leading to an increase of nosocomial infections in hospitalized patients (Boucher et al., 2009;
Rice, 2008; Spellberg et al., 2008). Infections by methicillin-resistant S. aureus (MRSA),
multidrug-resistant P. aeruginosa, and Vancomycin resistant E. faecium as well as various
strains ofMycobacterium tuberculosis causing multi-drug resistant tuberculosis (MDR-TB)
are a global health threat (Klevens et al., 2006; Pomerantz et al., 2001; NNIS, 2004). To
address this urgent and unmet medical need, new drugs acting on previously unexplored
targets need to be developed.
Although various enzymatic targets involved in bacterial metabolic pathways have been
investigated for antibiotic discovery, a large proportion of them remain unexplored: a
genomics-based selection, prioritization and a list of approximately one hundred essential
metabolic enzymes conserved across numerous diverse bacterial pathogens have been
revealed as potential new targets (Osterman & Begley, 2007; Payne et al., 2007). The degree
of conservation among orthologous sequences vary throughout the sequence and usually
have low sequence similarity on a full sequence alignment level as depicted in Fig. 1.
However, emphasis should be put on the residues involved in chemical interactions, that
is, residues forming the drug binding pocket given that slight variation in amino acids of
drug binding pockets responsible for enzymatic activity can cause considerable changes
in substrate and/or drug binding (Tytgat et al., 2009). We have previously compared
drug-binding pockets of various enzymes orthologs through sequence alignment and have
been successful in identifying new off-targets for receptors (McRobb et al., 2014; Ngo et al.,
2017). Species having conserved active sites might interact with inhibitors in similar way
that can be helpful for identification of inhibitors for diseases caused by the various species.
For illustration, the effect of active inhibitors on DapL orthologs like Arabidopsis thaliana
(AtDapL), a flowering plant, Leptospira interrogans (LiDapL), the soil/water bacterium
Verrucomicrobium spinosum (VsDapL) and the alga Chlamydomonas reinhardtii (CrDapL)
have been previously reported and it was found that AtDapL and LiDapL showed the
same trend of inhibition for different inhibitors in study. It clearly suggests that inhibitors
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Figure 1 Maps generated for full sequence identity calculation (A) Acetyl-coenzyme A carboxyl
transferase beta chain (AccC), (B) Beta-ketoacyl-acyl carrier protein synthase III (FabH), (C) Enoyl-
[acyl-carrier-protein] reductase [NADH] (FabI), (D) Dihydrofolate reductase (FolA), (E) 2-amino-
4-hydroxy-6-hydroxymethyldihydropteridine pyrophosphokinase (FolK), (F) D-alanine–D-alanine
ligase (ddlB), (G) 1-deoxy-D-xylulose 5-phosphate reductoisomerase (Dxr), (H) 1-deoxy-D-xylulose
5-phosphate synthase (Dxs), (I) 4-hydroxy-3-methylbut-2-enyl diphosphate reductase (IspH), (J)
Nicotinate-nucleotide adenylyltransferase (NADD), (K) Phosphopantetheine adenylyltransferase
(CoaD), (L) 6,7-dimethyl-8-ribityllumazine synthase (RibH). The edges are colored with a green (low
sequence) to blue (high sequence identity) gradient, where sequence identities between two nodes below
40% are not shown.
effective against one species may have potential of being active for other species as well
(McKinnie et al., 2014).
Since binding sites of enzymes from different species are generally more conserved than
their overall structures (Bartlett et al., 2002; Caffrey et al., 2004), we compared the drug
binding pockets of the key enzymes involved in selected essential metabolic pathways
conserved across the ESKAPE pathogens,M. tuberculosis, and other pathogenic and model
bacteria using experimentally determined crystal structures of representative orthologs
and amino acid sequence alignments. The majority of these selected enzymes lack human
orthologs (or close homologs), which is important for antibiotic discovery to minimize
side-effects via inhibition of respective host enzymes (Table 1). However this criteria
is not always absolute, as some antibiotics target specifically bacterial enzymes with
sufficient selectivity and have nearly no inhibitory effects on respective human ortholog.
For example, Trimethoprim is more potent inhibitor of bacterial dihydrofolate reductase
and have very weak inhibitory activity for human DHFR although its human ortholog
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Table 1 Enzymes, their abbreviations, their human counter targets, reference PDB used for analysis and inhibitors for twelve enzyme targets.
S.No Enzyme Abb Human counter targets Ref PDB Substrates or
compounds/
Speciesa
Presence PDB
1 Acetyl-coenzyme A carboxyl
transferase beta chain
AccC Distant
homolog:
domain of FasN
1XKT
(FASN),
5I87 (Acc2)
2V58 E. coli Biotin, Adenine
2 Beta-ketoacyl-acyl carrier
protein synthase III
FabH Distant
homolog:
domain of FasN
NA 1MZS E. coli Ceruleninpar
(Saccharomyces
cerevisiae)
3 Enoyl-[acyl-carrier-protein]
reductase [NADH]
FabI None NA 1QSG E. coli Triclosan
(Staphlococcus
aureus)
4 Dihydrofolate reductase Fol A Distant
homolog of
DHFR
4QHV 4NX6 E. coli Isoniazid (M.
tuberculosis),
Proguanil
(Plasmodium
falciparum)
Methotrexate
5 2-amino-4-hydroxy-6-
hydroxymethyldihydropteridine
pyrophosphokinase
Fol K None NA 4M5H E. coli Aminosalicylic
acid (M.
tuberculosis)
6 1-deoxy-D-xylulose 5-
phosphate synthase
Dxs None NA 2EGH E. coli –
7 4-hydroxy-3-methylbut-2-
enyl diphosphate reductase
IspH None NA 3ZGL E. coli –
8 1-deoxy-D-xylulose 5-
phosphate reductoisomerase
Dxr None NA 4NAL E. coli –
9 D-alanine–D-alanine ligase ddlB None NA 1IOW E. coli Cycloserine (M.
tuberculosis)
10 6,7-dimethyl-8-
ribityllumazine synthase
ribH None NA 2VI5M.
tuberculosis
–
11 Nicotinate-nucleotide
adenylyltransferase
NADD Distant
homolog,
NMNAT
1KR2 1K4M E. coli Niacin
12 Phosphopantetheine
adenylyltransferase
CoaD Distant
homolog
domain of
PPAT/DPCK
bifunctional
enzyme
3DO8
(Closer
homolog of
Human)
1B6T E. coli –
Notes.
Abb, abbreviation.
aAs found in Drugbank.
share 28% sequence identity (Sarker et al., 2012; Schweitzer, Dicker & Bertino, 1990). The
binding pocket residues of the relevant enzymes, defined by experimental crystal structures
captured in the Pocketome encyclopedia (Kufareva, Ilatovskiy & Abagyan, 2011), were
propagated onto a master alignment of the enzyme across different bacterial species.
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The results of this comparative analysis showed that specific enzymatic binding pockets
are highly identical (with sequence identity in the range of 70–100%) across some of
the ESKAPE pathogens suggesting that inhibitors designed to target one enzyme from
a particular bacterial species may have potential activity targeting the same enzyme in a
different species. In addition, this approach also enables selection of the most appropriate
model bacterial pathogens as a proxy for early stages of drug development and assists in
drug repurposing.
MATERIAL AND METHODS
Selection of pathogens
Nine different bacterial pathogens were selected including six ESKAPE pathogens,
namely Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter
baumannii, Pseudomonas aeruginosa and Enterobacter aurogenes. Mycobacterium
tuberculosis and two model non-pathogenic bacterial species Mycobacterium smegmatis
and Escherichia coli were also included in our binding pocket comparative analysis.
Selection of essential enzyme targets
Twelve essential and mostly conserved metabolic enzymes were selected as priority targets
for our study from a larger set of high-ranked metabolic drug targets based on previous
comparative and functional genomics analyses (Osterman & Begley, 2007) (Table 1).
These critical enzymes catalyze key steps in various metabolic pathways including folate
biosynthesis, fatty acid biosynthesis, isoprenoid biosynthesis, peptidoglycan biosynthesis,
nicotinamide adenine dinucleotide (NAD) and NADH biosynthesis, and riboflavin
metabolism. More importantly, our target selection was driven by the availability of
experimentally determined 3D structures and complexes of the respective protein target,
independent of the species. In addition to other criteria, the majority of these selected
enzymes lack human orthologs (or close homologs), which is important for antibiotic
discovery to minimize side effects via inhibition of respective host enzymes (Table 1).
Uniprot sequences and their alignment
The amino acid sequences of the selected enzymes for each of the respective bacterial
pathogens were obtained from the Uniprot database (The UniProt Consortium, 2017). The
sequences for each enzyme were then aligned using ICM v3.8-4a or above (Molsoft L.L.C.,
La Jolla, CA) (Abagyan & Totrov, 1994). The selected enzyme targets were matched against
the Pocketome encyclopedia (Kufareva, Ilatovskiy & Abagyan, 2011), which contains a set
of collected and annotated binding pocket structures derived from the Protein Data Bank
(PDB), allowing accurate, experimentally-derived definitions of their respective binding
pockets used for this analysis (Table 1).
Generation of distance-based maps for binding pocket sequence
identity comparison
Based on the full protein sequence, the sequence identity between each of the target enzymes
across each species was calculated; sequence identity wasmeasured as identical residue/total
number of aligned residues, transformed by the Dayhoff correction and distance-based
Naz et al. (2017), PeerJ, DOI 10.7717/peerj.3765 5/16
maps were generated in ICM. The binding pocket of each enzyme was determined by
the residue contacts made by small molecule inhibitors co-crystallized with an enzyme
from one of the selected pathogens. A subselection of the full sequence alignment was
extracted by propagating the determined binding pocket residues over orthologous protein
sequences of the selected pathogens. This followed binding pocket identity calculations
and regeneration of sequence maps based on the binding site as described above.
The labels used for various microorganisms were as followed: ENTFC for Enterococcus
faecium, STAAU for Staphylococcus aureus, KLEPN for Klebsiella pneumoniae, ACIBT for
Acinetobacter baumannii, PSEAE for Pseudomonas aeruginosa, ENTAE for Enterobacter
aurogenes, MYCTU forMycobacterium tuberculosis, MYCSM forMycobacterium smegmatis
and ECOLI for Escherichia coli.
Generation of homology model
A homology model was generated for the enzyme 1-deoxy-D-xylulose 5-phosphate
reductoisomerase (Dxr) from P. aeruginosa for predictive binding of known inhibitor
fosmidomycin into the binding pocket. The crystal structure of Dxr from Mycobacterium
tuberculosis (PDB ID: 4AIC) was used as the template (45% sequence identity). This model
was built by using the ICM homology modeling module.
RESULTS
Drug binding pocket conservation of enzymes involved in fatty acid
biosynthesis
Acetyl-Coenzyme A carboxylase (AccC) plays a key role in synthesis and degradation of
fatty acids. Targeting bacterial acetyl-CoA carboxylase can be an effective approach for
discovery of novel antibiotics with low side effects. Of the selected pathogens, acetyl-CoA
carboxylase (AccC) from E. coli has been crystallized (PDB: 2V58). The comparison of the
putative binding pockets based on the AccC E. coli crystal structure revealed that binding
pocket of AccC from E. coli (PDB: 2v58) (Miller et al., 2009) had 100% identity with its
ortholog in E. aurogenes and K. pneumoniae and up to 97% identity in P. aeruginosa and
A. baumannii. In comparison with the full-length sequence, the binding pocket of this
enzyme is highly conserved and interestingly, the level of conservation of drug binding
pocket is high among Gram-negative species (97–100%) as compared to Gram-positive
bacterial species like S. aureus and E. faecium (up to 74%) as depicted in Figs. 2A and 3A.
Beta-ketoacyl-acyl carrier protein synthase III (FabH) is another key enzyme involve
in fatty acid biosynthetic pathway. Using the FabH crystal structure from E. coli (PDB:
1MSZ) (Daines et al., 2003), the putative drug binding pocket of K. pneumoniae shared
89% identity with the co-crystallized structure whilst the drug binding pockets of FabH
among all species in the study have high identity (77–100%) as suggested by the maps
(Fig. 2B). Previously, 4,5-dichloro-1,2-dithiole-3-one was reported as potent inhibitor of
FabH from S. aureus but also in E. coli, further supporting our hypothesis that inhibitors
effective in one species have potential off target activity against other species (He et al.,
2004).
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Figure 2 Maps generated for Drug Binding Pocket sequence identity calculation for (A) Acetyl-
coenzyme A carboxyl transferase beta chain (AccC), (B) Beta-ketoacyl-acyl carrier protein synthase
III (FabH), (C) Enoyl-[acyl-carrier-protein] reductase [NADH] (FabI), (D) Dihydrofolate reductase
(FolA), (E) 2-amino-4-hydroxy-6-hydroxymethyldihydropteridine pyrophosphokinase (FolK), (F)
D-alanine–D-alanine ligase (ddlB), (G) 1-deoxy-D-xylulose 5-phosphate reductoisomerase (Dxr),
(H) 1-deoxy-D-xylulose 5-phosphate synthase (Dxs), (I) 4-hydroxy-3-methylbut-2-enyl diphosphate
reductase (IspH), (J) Nicotinate-nucleotide adenylyltransferase (NADD), (K) Phosphopantetheine
adenylyltransferase (CoaD), (L) 6,7-dimethyl-8-ribityllumazine synthase (RibH). The edges are colored
with a green (low sequence) to blue (high sequence identity) gradient, where sequence identities between
two nodes below 50% are not shown.
The binding pocket of enoyl-acyl carrier protein reductase (FabI) is highly conserved
among various species as compared to the overall sequence. By using the E. coli FabI crystal
structure (PDB: 1QSG) (Stewart et al., 1999), we found that the respective FabI ortholog
putative binding pockets in E. aurogenes, K. pneumoniae, P. aeruginosa, A. baumannii
were 100% identitical to one another, while sharing greater than 80% sequence identity
compared to the putative FabI pocket E. faecium andM. tuberculosis (Fig. 2C).
Drug binding pocket conservation of enzymes involved in folate
synthesis
The sequence of drug binding pockets of key enzyme dihydrofolate reductase (folA) of
folate biosynthesis were found to be highly conserved (81–100%) among various ESKAPE
pathogens by using PDB: 4NX6 from E.coli for comparison and the same trend was
observed in case of 6-Hydroxymethyl-7,8-dihydropterin pyrophosphokinase (folK) except
S. aureus with reference PDB: 4M5H (Figs. 2D and 2E).
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Figure 3 Multiple sequence alignment for drug binding pockets of Enzymes (A) Acetyl-coenzyme
A carboxyl transferase beta chain (AccC), (B) Beta-ketoacyl-acyl carrier protein synthase III (FabH),
(C) Enoyl-[acyl-carrier-protein] reductase [NADH] (FabI), (D) Dihydrofolate reductase (FolA), (E) 2-
amino-4-hydroxy-6-hydroxymethyldihydropteridine pyrophosphokinase (FolK), (F) D-alanine–D-
alanine ligase (ddlB), (G) 1-deoxy-D-xylulose 5-phosphate reductoisomerase (Dxr), (H) 1-deoxy-D-
xylulose 5-phosphate synthase (Dxs), (I) 4-hydroxy-3-methylbut-2-enyl diphosphate reductase (IspH),
(J) Nicotinate-nucleotide adenylyltransferase (NADD), (K) Phosphopantetheine adenylyltransferase
(CoaD), (L) 6,7-dimethyl-8-ribityllumazine synthase (RibH). The residue numbers in the alignments are
in reference to the E. coli protein.
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Drug binding pocket conservation of enzymes involved in isoprenoid
biosynthesis
The species S. aureus and E. faecium involve the mevalonate pathway for isoprenoid
biosynthesis so they lack the Dxs, Dxr and IspH enzymes. The amino acid residues involved
in ligand interactions of 1-deoxy-D-xylulose 5-phosphate synthase (Dxs) from E.coli (PDB:
2EGH) (Yajima et al., 2007) showed sequence identity values below 70% among various
bacterial species in current comparison. The other two enzymes of non-mevalonate
pathway like IspH and Dxr showed 98–100% conservation of amino acid sequence among
all species in comparison based on the crystal structures PDB: 3ZGL and PDB: 3ANL (Deng
et al., 2010) from E.coli respectively (Figs. 2G–2I).
Drug binding pocket conservation of enzymes involved in
peptidoglycan and CoA biosynthesis
D-alanyl-D-alanine ligase (ddlB) is a significant target for antibiotic discovery as it is
essential for bacterial growth. Propagating the drug binding pocket of ddlB from E.coli
(PDB: 1IOW) (Fan et al., 1997) onto all the other species, it revealed that they all shared
96–100% sequence identity amongst one another as shown in Fig. 2F.
Phosphopantetheine adenylyltransferase (CoaD) enzyme involved in coenzyme A
biosynthesis is another attractive target for antibiotic discovery. Similarly, the drug binding
pocket of Phosphopantetheine adenylyltransferase based on PDB: 1B6T (Izard & Geerlof,
1999) was found to be highly conserved amongst the ESKAPE,Mycobacterium tuberculosis
as well as other bacterial species in the range of 85–100% as compared to full sequence
(Figs. 1 and 2K).
Drug binding pocket conservation of NADD and 6,7-dimethyl-8
-ribityllumazine synthase enzyme
The drug binding pocket of co-crystal structure of NADD from E. coli (PDB: 1K4M)
(Zhang et al., 2002) showed 100% identity with all the species in this comparison, except
A. baumannii, while the inhibitor binding pocket of the enzyme ribH, which catalyzes a key
step in metabolism of Riboflavin resulting in synthesis of flavin mononucleotide (FMN)
and flavin adenine dinucleotide (FAD) cofactors, was conserved (90–100%) across the
various species as compared to reference binding pocket (PDB: 2VI5) (Zhang et al., 2008)
(Figs. 2J and 2L).
Comparison of fosmidomycin interaction with Dxr binding pockets
across various species
From the ChEMBL dataset of active compounds for the enzyme 1-deoxy-D-xylulose
5-phosphate reductoisomerase (Dxr), we found that Fosmidomycin, a natural antibiotic,
is an inhibitor for Dxr in both E.coli and M. tuberculosis. Crystal structures of E.coli
and M. tuberculosis Dxr have been solved with Fosmidomycin (PDB ID: 1ONP and
4AIC respectively) and they display a similar shape and orientation in three-dimensional
space (Henriksson et al., 2007; Steinbacher et al., 2003) (Figs. 4A and 4B). In addition,
the inhibitor showed similar, if not identical, interactions with binding pocket residues
(Fig. 4C); they display 41% sequence identity across the full length sequence, which further
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Figure 4 (A) Binding interaction of drug binding pocket of Dxr from E.coli (PDB: 1ONP), (B) Bind-
ing interaction of drug binding pocket of Dxr fromM. tuberculosis (PDB: 4AIC), (C) Binding of Fos-
midomycin in pocket of model generated for Uniprot sequence of Dxr from P. aeruginosa, (D) Binding
pocket interaction of oxacillin co-crystallized with β-lactamase from A. baumannii, (E) Binding pocket in-
teraction of oxacillin co-crystallized with β-lactamase from E. coli.
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strengthens our hypothesis that inhibitors active in one species may have activity for other
enzyme orthologs. As Fosmidomycin has shown activity against Dxr ofM. tuberculosis and
E. coli, this will help the design of new drugs for tuberculosis by taking advantage of the
fosmidomycin chemical scaffold. Fosmidomycin and its derivatives has also been reported
as potent inhibitors of Dxr of P. falciparum, the causative agent of malaria. To predict its
interaction-binding mode, we generated homology model of Dxr from P. aeruginosa using
PDB: 4AIC as a template and docked Fosmidomycin into the putative binding pocket. The
highest ranked docking pose predicted a similar interaction pattern compared to the crystal
structures (Fig. 4C). In another example, oxacillin, a β-lactam antibiotic of the penicillin
group has been co-crystallized with the Class D β-lactamases oxacillinase OXA-1 from
E. coli and OXA-24/40 from A. baumannii (which shares 99% full length sequence identity
with OXA-1) (PDB ID: 4MLL and 4F94, respectively) (June et al., 2014). The comparison
of the ligand binding pockets display similar orientation (with slight rotation of an R side
chain group between the structures), binding interactions, as well as shape (June et al.,
2014) as depicted in Figs. 4D and 4E. The examples of fosmidomycin and oxacillin further
demonstrates the idea of conserved binding pockets and cross-species activity.
DISCUSSION
The current study compared the putative binding pockets of awide range of broad-spectrum
antibacterial targets selected from the set of essential metabolic enzymes, conserved across
the group of ESKAPE pathogens. On the assumption that enzymes share a common
binding pocket spatially, we propagated experimentally determined drug binding pockets of
enzymes of one pathogen onto all other important pathogens by alignment. We performed
comparison at the level of full sequence and for drug binding pockets and found that the
binding pocket sequences were highly conserved across the ESKAPE pathogens (Fig. 2
and 3). Although the percent sequence identity calculated for full sequence alignment for
all these enzymes was still reasonable (Fig. 1), the binding pocket comparison revealed a
high degree, if not, full conservation, which suggests that there is potential for off-target
activity by these inhibitors and allow the ease of drug repurposing and expansion of disease
indications.
Generally, key metabolic enzymes from the ESKAPE pathogens displayed conserved
binding pockets (extrapolated from experimentally-determined structures) across various
bacterial species. This suggests that inhibitors, which are effective for one species has
the potential to be active for other species, providing ligand design cues for broad-range
inhibitors. In addition, binding pockets of enzymes including ddlB, CoaD, FabH, FabI,
FolA and IspH showed high sequence identity, not only across the ESKAPE pathogens, but
also with M. tuberculosis, which will ultimately guide the identification of new inhibitors
against tuberculosis (Fig. 2). In particular, the binding pocket of IspH showed 100%
sequence identity among all species in this comparison (Fig. 2) and, thus, known inhibitors
of IspH enzymes is a suitable initial ligand screening set for all bacterial species. There
is a precedent, where N-[2,4-Dioxo-6-D-ribitylamino-1,2,3,4-tetrahydropyrimidin-5-yl]
oxalamic acid derivatives were screened and inhibited orthologs of enzyme lumazine
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synthase from M. tuberculosis, B. subtilis and E.coli (Zhang et al., 2008). Therefore, the
concept of taking the same inhibitor for different bacterial species and different diseases is
useful for the identification of new antibiotics with off target activity.
There are several limitations of this study that need to be considered. Our method is
heavily reliant on the availability of at least one crystal structure of the enzyme of interest
for accurate interspecies binding pocket comparison, which excludes many potential drug
targets. Furthermore, the method is reliant on good sequence alignment of the various
enzyme orthologs and does not consider whether these enzymes have similar functions
in their respective bacterial species. These limitations will be addressed in the future with
the increasing availability of structural data. The incorporation of spatial information
and protein folding in the form of homology models, as we have demonstrated for
fosmidomycin interactions with Dxr of P. aeruginosa, can be used to extend our analysis
in the future. In addition, the sequence maps also showed that the binding site of ESKAPE
pathogens are closely related to each other; these are all in silico predictions and will require
experimental validation, which is beyond the scope of this study. However, we believe this
could be a new direction for discovering or repurposing new inhibitors for enzyme targets
of different orthologs based on inferred binding pocket identity or similarity. Furthermore,
we have also focused on essential enzymes here, whereas the bigger challenge is identifying
targets, which are less prone to resistance, which will be investigated in future studies.
CONCLUSIONS
The present investigation demonstrated that putative drug binding pockets of key enzymes
of ESKAPE pathogens have a higher degree of conservation than full length sequences,
based on the extrapolation of experimentally-determined binding pockets of orthologs. We
propose that conserved pocket sequence identity will mean that drugs or ligands interacting
at one pocket will display the same inhibition at another and that the same chemical scaffold
can be used as the basis of drug design for other enzyme orthologs. This potentially could
be an effective approach for design of new antibiotics for ESKAPE pathogens.
ACKNOWLEDGEMENTS
We thank Andrei Osterman, Irina Kufareva and Andrey Ilatovskiy for stimulating
discussions and for their help with target selection and the Pocketome database. We
also thank Chris Edwards for his help and support.
ADDITIONAL INFORMATION AND DECLARATIONS
Funding
The work was supported by an IRSIP scholarship of Pakistan granted to Sadia Naz. Ruben
Abagyan is supported by NIH Grant R01 GM071872. The funders had no role in study
design, data collection and analysis, decision to publish, or preparation of the manuscript.
Naz et al. (2017), PeerJ, DOI 10.7717/peerj.3765 12/16
Grant Disclosures
The following grant information was disclosed by the authors:
IRSIP scholarship of Pakistan.
NIH: R01 GM071872.
Competing Interests
Ruben Abagyan has an equity interest in Molsoft, LLC. The terms of this arrangement have
been reviewed and approved by the University of California, San Diego, in accordance with
its conflict of interest policies.
Author Contributions
• Sadia Naz conceived and designed the experiments, performed the experiments, analyzed
the data, wrote the paper, prepared figures and/or tables.
• Tony Ngo analyzed the data, wrote the paper, prepared figures and/or tables, reviewed
drafts of the paper.
• Umar Farooq conceived and designed the experiments, reviewed drafts of the paper.
• Ruben Abagyan conceived and designed the experiments, analyzed the data, contributed
reagents/materials/analysis tools, reviewed drafts of the paper.
Data Availability
The following information was supplied regarding data availability:
All alignment fasta files used to calculate sequence identities have been included as
Supplementary Files.
Supplemental Information
Supplemental information for this article can be found online at http://dx.doi.org/10.7717/
peerj.3765#supplemental-information.
REFERENCES
Abagyan R, TotrovM. 1994. Biased probability Monte Carlo conformational searches
and electrostatic calculations for peptides and proteins. Journal of Molecular Biology
235:983–1002 DOI 10.1006/jmbi.1994.1052.
Bartlett GJ, Porter CT, Borkakoti N, Thornton JM. 2002. Analysis of catalytic
residues in enzyme active sites. Journal of Molecular Biology 324:105–121
DOI 10.1016/S0022-2836(02)01036-7.
Boucher HW, Talbot GH, Bradley JS, Edwards JE, Gilbert D, Rice LB, ScheldM,
Spellberg B, Bartlett J. 2009. Bad bugs, no drugs: no ESKAPE! An update from
the Infectious Diseases Society of America. Clinical Infectious Diseases 48:1–12
DOI 10.1086/595011.
Caffrey DR, Somaroo S, Hughes JD, Mintseris J, Huang ES. 2004. Are protein–protein
interfaces more conserved in sequence than the rest of the protein surface? Protein
Science 13:190–202 DOI 10.1110/ps.03323604.
Naz et al. (2017), PeerJ, DOI 10.7717/peerj.3765 13/16
Daines RA, Pendrak I, ShamK, Van Aller GS, Konstantinidis AK, Lonsdale JT, Janson
CA, Qiu X, Brandt M, Khandekar SS. 2003. First X-ray cocrystal structure of a
bacterial FabH condensing enzyme and a small molecule inhibitor achieved using
rational design and homology modeling. Journal of Medicinal Chemistry 46:5–8
DOI 10.1021/jm025571b.
Deng L, Endo K, KatoM, Cheng G, Yajima S, Song Y. 2010. Structures of 1-deoxy-D-
xylulose-5-phosphate reductoisomerase/lipophilic phosphonate complexes. ACS
Medicinal Chemistry Letters 2:165–170 DOI 10.1021/ml100243r.
Fan C, Park I-S, Walsh CT, Knox JR. 1997. D-alanine: D-alanine ligase: phosphonate
and phosphinate intermediates with wild type and the Y216F mutant. Biochemistry
36:2531–2538 DOI 10.1021/bi962431t.
He X, Reeve AM, Desai UR, Kellogg GE, Reynolds KA. 2004. 1, 2-dithiole-3-
ones as potent inhibitors of the bacterial 3-ketoacyl acyl carrier protein syn-
thase III (FabH). Antimicrobial Agents and Chemotherapy 48:3093–3102
DOI 10.1128/AAC.48.8.3093-3102.2004.
Henriksson LM, Unge T, Carlsson J, Åqvist J, Mowbray SL, Jones TA. 2007. Structures
ofMycobacterium tuberculosis 1-deoxy-D-xylulose-5-phosphate reductoisomerase
provide new insights into catalysis. Journal of Biological Chemistry 282:19905–19916
DOI 10.1074/jbc.M701935200.
Izard T, Geerlof A. 1999. The crystal structure of a novel bacterial adenylyltransferase
reveals half of sites reactivity. The EMBO Journal 18:2021–2030
DOI 10.1093/emboj/18.8.2021.
June CM, Vallier BC, Bonomo RA, Leonard DA, Powers RA. 2014. Structural origins of
oxacillinase specificity in class D β-lactamases. Antimicrobial Agents and Chemother-
apy 58:333–341 DOI 10.1128/AAC.01483-13.
Klevens RM, Edwards JR, Tenover FC, McDonald LC, Horan T, Gaynes R, System
NNIS. 2006. Changes in the epidemiology of methicillin-resistant Staphylococcus
aureus in intensive care units in US hospitals, 1992–2003. Clinical Infectious Diseases
42:389–391 DOI 10.1086/499367.
Kufareva I, Ilatovskiy AV, Abagyan R. 2011. Pocketome: an encyclopedia of small-
molecule binding sites in 4D. Nucleic Acids Research 40:535–540
DOI 10.1093/nar/gkr825.
McKinnie SM, Rodriguez-Lopez EM, Vederas JC, Crowther JM, Suzuki H, Dobson
RC, Leustek T, Triassi AJ, Wheatley MS, Hudson AO. 2014. Differential response
of orthologous L, L-diaminopimelate aminotransferases (DapL) to enzyme in-
hibitory antibiotic lead compounds. Bioorganic & Medicinal Chemistry 22:523–530
DOI 10.1016/j.bmc.2013.10.055.
McRobb FM, Sahagún V, Kufareva I, Abagyan R. 2014. In silico analysis of the con-
servation of human toxicity and endocrine disruption targets in aquatic species.
Environmental Science & Technology 48:1964–1972 DOI 10.1021/es404568a.
Miller JR, Dunham S, Mochalkin I, Banotai C, BowmanM, Buist S, Dunkle B, Hanna
D, Harwood HJ, HubandMD. 2009. A class of selective antibacterials derived from a
Naz et al. (2017), PeerJ, DOI 10.7717/peerj.3765 14/16
protein kinase inhibitor pharmacophore. Proceedings of the National Academy of Sci-
ences of the United States of America 106:1737–1742 DOI 10.1073/pnas.0811275106.
Ngo T, Ilatovskiy AV, Stewart AG, Coleman JLJ, McRobb FM, Riek RP, Graham RM,
Abagyan R, Kufareva I, Smith NJ. 2017. Orphan receptor ligand discovery by
pickpocketing pharmacological neighbors. Nature Chemical Biology 13:235–242
DOI 10.1038/nchembio.2266.
NNIS. 2004. National Nosocomial Infections Surveillance (NNIS) System Report, data
summary from January 1992 through June 2004, issued October 2004. American
Journal of Infection Control 32:470–485 DOI 10.1016/j.ajic.2004.10.001.
Osterman AL, Begley TP. 2007. A subsystems-based approach to the identification of
drug targets in bacterial pathogens. In: Systems biological approaches in infectious
diseases. Basel: Springer, 131–170.
Payne DJ, GwynnMN, Holmes DJ, Pompliano DL. 2007. Drugs for bad bugs: con-
fronting the challenges of antibacterial discovery. Nature Reviews Drug Discovery
6:29–40 DOI 10.1038/nrd2201.
Pomerantz BJ, Cleveland JC, Olson HK, Pomerantz M. 2001. Pulmonary resection for
multi–drug resistant tuberculosis. The Journal of Thoracic and Cardiovascular Surgery
121:448–453 DOI 10.1067/mtc.2001.112339.
Rice LB. 2008. Federal funding for the study of antimicrobial resistance in noso-
comial pathogens: no ESKAPE. Journal of Infectious Diseases 197:1079–1081
DOI 10.1086/533452.
Sarker M, Talcott C, Madrid P, Chopra S, Bunin BA, Lamichhane G, Freundlich
JS, Ekins S. 2012. Combining cheminformatics methods and pathway analysis
to identify molecules with whole-cell activity againstMycobacterium tuberculosis.
Pharmaceutical Research 29:2115–2127 DOI 10.1007/s11095-012-0741-5.
Schweitzer BI, Dicker AP, Bertino JR. 1990. Dihydrofolate reductase as a therapeutic
target. The FASEB Journal 4:2441–2452.
Spellberg B, Guidos R, Gilbert D, Bradley J, Boucher HW, ScheldWM, Bartlett JG,
Edwards J, America IDSo. 2008. The epidemic of antibiotic-resistant infections:
a call to action for the medical community from the Infectious Diseases Society of
America. Clinical Infectious Diseases 46:155–164 DOI 10.1086/524891.
Steinbacher S, Kaiser J, EisenreichW, Huber R, Bacher A, Rohdich F. 2003. Structural
basis of fosmidomycin action revealed by the complex with 2-C-methyl-D-erythritol
4-phosphate synthase (IspC) Implications for the catalytic mechanism and anti-
malaria drug development. Journal of Biological Chemistry 278:18401–18407
DOI 10.1074/jbc.M300993200.
Stewart MJ, Parikh S, Xiao G, Tonge PJ, Kisker C. 1999. Structural basis and mechanism
of enoyl reductase inhibition by triclosan. Journal of Molecular Biology 290:859–865
DOI 10.1006/jmbi.1999.2907.
The UniProt Consortium. 2017. UniProt: the universal protein knowledgebase. Nucleic
Acids Research 45:D158–D169 DOI 10.1093/nar/gkw1099.
Naz et al. (2017), PeerJ, DOI 10.7717/peerj.3765 15/16
Tytgat I, Colacino E, Tulkens PM, Poupaert JH, Prévost M, Van Bambeke F. 2009. DD-
ligases as a potential target for antibiotics: past, present and future. Current Medicinal
Chemistry 16:2566–2580 DOI 10.2174/092986709788682029.
Yajima S, Hara K, Iino D, Sasaki Y, Kuzuyama T, Ohsawa K, Seto H. 2007. Structure
of 1-deoxy-D-xylulose 5-phosphate reductoisomerase in a quaternary complex
with a magnesium ion, NADPH and the antimalarial drug fosmidomycin. Acta
Crystallographica Section F 63:466–470 DOI 10.1107/S1744309107024475.
Zhang Y, Illarionov B, Morgunova E, Jin G, Bacher A, Fischer M, Ladenstein R,
CushmanM. 2008. A new series of N-[2, 4-dioxo-6-d-ribitylamino-1, 2, 3, 4-
tetrahydropyrimidin-5-yl] oxalamic acid derivatives as inhibitors of lumazine
synthase and riboflavin synthase: design, synthesis, biochemical evaluation,
crystallography, and mechanistic implications. The Journal of Organic Chemistry
73:2715–2724 DOI 10.1021/jo702631a.
Zhang H, Zhou T, Kurnasov O, Cheek S, Grishin NV, Osterman A. 2002. Crystal
structures of E. coli nicotinate mononucleotide adenylyltransferase and its complex
with deamido-NAD. Structure 10:69–79 DOI 10.1016/S0969-2126(01)00693-1.
Naz et al. (2017), PeerJ, DOI 10.7717/peerj.3765 16/16
